Study Finds Certain Antiviral Drugs, mAb Therapies Lower Mortality Risk, Reduce Hospitalization Among Individuals Infected With SARS-CoV-2 Omicron Variant And Certain Omicron Subvariants

Pulmonology Advisor (2/7, Goldberg) reported, “Certain antiviral drugs and monoclonal antibody (mAb) therapies continue to lower mortality risk and reduce hospitalization among individuals infected with the SARS-CoV-2 Omicron variant and certain Omicron subvariants, according to systematic review and meta-analysis study findings.” The researchers said, “Among individuals infected with COVID-19 during the Omicron wave, mortality risk was lower with nirmatrelvir/ritonavir or sotrovimab use, whereas hospitalization was reduced with nirmatrelvir/ritonavir, remdesivir, or sotrovimab.” The findings were published in Influenza and Other Respiratory Viruses.